Advancing Hepatic ADME with Predictive In Vitro Models
MileCell is pleased to announce its participation as a Bronze Sponsor at the 2026 Great Lakes Drug Metabolism & Disposition Group (GLDMDG) Meeting, taking place May 7–8, 2026, at the Chicago Botanic Garden in Glencoe, Illinois.
The GLDMDG meeting brings together scientists from pharmaceutical companies, biotechnology firms, and academic institutions to facilitate the exchange of ideas in drug metabolism and disposition (DMPK). The meeting is widely recognized for its focus on scientific discussion and collaboration across key areas of ADME research.
As drug discovery increasingly depends on physiologically relevant and reproducible in vitro systems, the selection of high-quality hepatic models plays a critical role in generating reliable data for ADME and DMPK studies.
At this year’s meeting, MileCell will highlight its primary cell-based solutions for hepatic ADME research, including:
These solutions are designed to support a wide range of applications, including metabolic stability, enzyme induction and inhibition studies, and translational research workflows.
MileCell looks forward to engaging with researchers and industry partners at GLDMDG 2026 and discussing how its hepatic ADME platforms can support more predictive and reliable drug development.
Event Details
📍 Chicago Botanic Garden, Glencoe, IL
📅 May 7–8, 2026
About MileCell
MileCell is dedicated to advancing life science research through high-quality primary cell solutions, including hepatocytes, non-parenchymal cells, subcellular fractions, and cell processing reagents. With a focus on ADME, toxicology, and cell & gene therapy research, MileCell supports scientists worldwide in generating reliable and translational data.